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Background: We previously demonstrated that celastrol has significant
anti-inflammatory and bone protective effects when administered via the intraperitoneal
route. For further preclinical evaluation, an effective oral administration of celastrol is
crucial. Here we aimed to study the therapeutic dose range for its oral administration.
Methods: Celastrol (1–25 µg/g/day, N = 5/group) was administrated orally to female
adjuvant-induced arthritis (AIA) rats after 8 days of disease induction for a period of 14
days. A group of healthy (N = 8) and arthritic (N = 15) gender- and age-matched Wistar
rats was used as controls. During the treatment period, the inflammatory score, ankle
perimeter, and body weight were measured. At the end of the treatment, the animals
were sacrificed, blood was collected for clinical pathology, necropsy was performed with
collection of internal organs for histopathological analysis, and paw samples were used
for disease scoring.
Results: Doses higher than 2.5 µg/g/day of celastrol reduced the inflammatory score
and ankle swelling, preserved joint structure, halted bone destruction, and diminished
the number of synovial CD68+ macrophages. Bone resorption and turnover were
also reduced at 5 and 7.5 µg/g/day doses. However, the dose of 7.5 µg/g/day was
associated with thymic and liver lesions, and higher doses showed severe toxicity.
Conclusion: Oral administration of celastrol above 2.5 µg/g/day ameliorates arthritis.
This data supports and gives relevant information for the development of a preclinical
test of celastrol in the setting of a chronic model of arthritis since rheumatoid arthritis is
a long-term disease.
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INTRODUCTION
The therapeutic effect of celastrol has been demonstrated
in several inflammatory diseases. Celastrol is a pentacyclic-
triterpene compound that can be found in root extracts from
Tripterygium wilfordii (TW) (1), an herb used in Chinese
medicine (2–4).
In the last 5 years, increasing evidence for the therapeutic
potential of celastrol in the treatment of rheumatoid arthritis
(RA) has emerged. Studies have suggested that the anti-
inflammatory properties of celastrol can be mainly attributed to
the regulation of cytokine production (5–8), the modulation of
inflammatory cells (8–13), the inhibition of osteoclastogenesis,
and bone protection (8, 14–16), mostly due to its ability to
downregulate the NF-kB pathway.
Specifically, we have demonstrated that the intraperitoneal
administration of celastrol suppressed inflammatory signs (7),
preserved joint structure, with abrogation of the inflammatory
infiltrate and cellular proliferation (7, 8), and halted focal bone
damage in the adjuvant-induced arthritis (AIA) rat model (8, 17).
This inhibitory effect of cellular infiltration and proliferationmay
prove to be of interest to treat the development of the synovial
tumor-like pannus tissue characteristic of RA, one of the main
contributors to bone damage. Importantly, we have reported
that this compound is able to significantly decrease the number
of sublining CD68+ synovial macrophages (8), a biomarker of
treatment efficacy in RA (18–20). So far, we observed that the
intraperitoneal administration of celastrol to AIA rats was not
associated with overt signs of toxicity (8).
Despite the therapeutic potential of celastrol, further clinical
application seems to be limited by poor water solubility (21),
low oral bioavailability (22), possible side effects (23–26), and
variability in dose regimens (9, 27–30).
Therefore, in order to advance the preclinical development of
celastrol as a candidate therapeutic compound for RA treatment,
we analyzed the therapeutic dose range for oral administration of
pure celastrol using the AIA rat model.
MATERIALS AND METHODS
Animals
The AIA model has been the most extensively used arthritic
rat model to study anti-arthritic agents because it has an
excellent track record for predicting both activity and toxicity.
AIA rats share key features related to RA, making them a
critical tool in drug development, and exhibit the greatest
magnitude of disease when compared with other models of
arthritis (31). Eight-week-old female Wistar AIA rats weighing
230–250 g were purchased from Charles River Laboratories
International (Massachusetts, USA). Charles River Laboratories
performed the induction of adjuvant disease using Freud’s
complete adjuvant, supplemented with mycobacterium, and
injected in the right footpad. The AIA rats were maintained
under specific-pathogen-free conditions, randomly housed per
group under standard laboratory conditions (at 22◦C under
10-h light/14-h dark conditions), and given free access to food
(RM3, SDS Diets, UK) and water (ultrapure). In addition,
to minimize animal discomfort, paper shavings were used as
bedding material in Double Decker GR1800 cages (Techniplast,
UK) with five animals each. The criteria for a humane sacrifice
were determined as previously published (8), and the animals
were sacrificed when presenting the maximum inflammatory
score in more than two limbs or when weight loss exceeded 20%.
In accordance with Directive 2010/63/EU, all animal procedures
were approved by the institutional animal welfare body (ORBEA-
iMM) and licensed by the Portuguese competent authority
(DGAV—Direcção Geral de Alimentação e Veterinária, license
number: 0421/000/000/2016).
Celastrol Preparation and Administration
Celastrol (Sigma, Missouri, USA) stock solution of 10 mg/ml was
prepared using ethanol 100% as solvent (vehicle). A recent study
has tested the solubility of celastrol in different vehicles, and we
have previously demonstrated that ethanol is one of the most
efficient solvents for this compound (21). This celastrol stock
solution was further dissolved in PEG400 (Sigma, St. Louis, USA)
(1, 2.5, 5, 7.5, 12.5, and 25µg/g in 1ml) and administrated by oral
gavage to AIA rats for 14 consecutive days (N = 5 rats/group).
The sample size in each group was calculated using free sample
size calculating G∗Power version 3.1.9.2 software [type of power
analysis: a priori; α error probability: 0.05; power (1-β error
probability): 0.95; effect size d: 2.59; actual power: 0.976]. This
calculation was based on our own previous data (7, 8, 17).
Our study was approved by the institutional animal welfare
body, licensed by the Portuguese competent authority, and
complied with good ethical, scientific, legal, and economic
reasons for using laboratory animals, including the 3R principle
(replace, reduce, and refine). Focused on the “reduce” rule, we
used the minimum number of animals, calculated by the free
sample size calculating G∗Power software, in order to perform
this study.
The need for daily administrations is supported by the study
of Zhang et al., which showed that the half-life of pure celastrol is
∼10 h (22). Based on this publication, we have also calculated the
oral dose of 2.5 µg/g/day as the equivalent to the intraperitoneal
dose of 1 µg/g/day that we had previously found to be effective
in the treatment of arthritis in the same rat model (7, 8).
The calculation was based on the fraction of the celastrol dose
absorbed in the portal blood after oral administration, which was
17.6%. Intraperitoneal dose calculation took into consideration
that the intraportal dose will have higher bioavailability.
Therefore, the relationship between the area under the curve
and the doses administered in the oral and the intraportal dose
was used for determining the intraperitoneal dose. Treatment
was initiated after 8 days of disease induction, at the acute
clinical stage of arthritis progression (therapeutic intervention)
(32). Healthy non-arthritic (N = 8) and arthritic untreated
(N = 15) female age-matched Wistar rats were used as controls.
The arthritic untreated group received an equal volume of vehicle
through oral gavage. The vehicle proportion of ethanol and
PEG400 used was in the same proportion as the one used in the
celastrol-treated groups.
The rats were sacrificed after 22 days of disease
progression by CO2 narcosis, and blood, internal
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organs, as well as paw samples were collected. Studies
using the AIA model are generally completed at this
time point due to a plateau effect of inflammatory
manifestations (7, 31).
Arthritis Severity Evaluation
Disease activity was clinically evaluated during the period
of treatment by two independent investigators using an
inflammatory score and by measuring the ankle perimeter
as readout of articular swelling. The inflammatory score
was measured by counting the score of each limb joint
in a scale of 0–3 (0—absence, 1—erythema, 2—erythema
and swelling, and 3—deformities and functional impairment).
The total score for each animal was defined as the sum
of the partial scores of each affected joint (7, 33). Body
weight was also registered, every 2 days, throughout the
experimental procedure.
Clinical Pathology and Histological
Analysis
Blood was collected from the heart and used for serum
biochemistry measurement of creatine kinase (CK),
urea, lactate dehydrogenase (LDH), alanine transaminase
(ALT) (BioAssay Systems, California, USA), and pro-
ANP (Biomedica, Viena, Austria) by enzyme-linked
immunosorbent assay (ELISA) technique, according to the
manufacturer’s instructions. The ELISA measurement was
performed using the plate reader Infinite M200 (Tecan,
Mannedorf, Switzerland).
Necropsy was performed, and the left hind paw was
collected for tibiotarsal joint histopathological analysis and
disease scoring, and the liver, spleen, kidney, lung, thymus,
heart, gastrointestinal tract, and long bone (humerus)
were collected for routine histopathological analysis
to assess signs of celastrol-induced toxicity. Briefly, all
organs and tissues were immediately fixed in 10% neutral
buffered formalin, the bones were further decalcified
in 10% formic acid, and all samples were processed for
paraffin embedding.
For histological disease activity scoring, serial 5-µm sections
of the tibiotarsal joints were stained with hematoxylin and
eosin (H&E) and immunohistochemistry was performed
using the following antibodies: mouse monoclonal anti-CD68
(Abcam, Cambridge, UK), mouse monoclonal anti-osteocalcin
(osteoblast marker; indicator of osteoblastic activity; Abcam,
Cambridge, UK), rabbit polyclonal anti-cathepsin K (osteoclast
marker; mature osteoclast enzyme; Biorbyt, Cambridge,
UK), and rabbit polyclonal anti-Ki67 (Abcam, Cambridge,
UK) antibodies. The tissue sections were incubated with
the primary antibody and with EnVision+ (Dako, Glostrup,
Denmark). Color was developed in a solution containing
diaminobenzadine-tetrahydrochloride (Sigma, Missouri, USA)
and 0.5% H2O2 in phosphate-buffered saline buffer (pH
7.6). The slides were counterstained with hematoxylin and
mounted. Histological disease activity scoring in the tibiotarsal
joints was performed by an independent researcher blinded
to the experimental groups using four semi-quantitative
scores, as previously published: sublining layer infiltration
score (0—none to diffuse infiltration, 1—lymphoid cell
aggregate, 2—lymphoid follicles, and 3—lymphoid follicles
with germinal center formation), lining layer cell number
score (0—fewer than three layers, 1—three to four layers,
2—five to six layers, and 3—more than six layers), bone
erosion score (0—no erosions, 1—minimal, 2—mild, 3—
moderate, and 4—marked), and global disease severity score
(0—no signs of inflammation, 1—mild, 2—moderate, and
3—severe) (7, 34, 35). The proliferation of synoviocytes was
also analyzed using a semi-quantitative score (0–4) of Ki67
immunostaining (0—no stained cells, 1−0–25% staining,
2−25–50% staining, 3−50–75% staining, and 4—more than 75%
stained cells) (7). Images were acquired in a Leica DM2500 (Leica
Microsystems, Wetzlar, Germany) coupled to a Leica MC170
HD microscope camera.
For the assessment of celastrol-induced toxicity, 4-µm
sections of the liver, spleen, kidney, lung, thymus, heart,
gastrointestinal tract, and humerus were stained with H&E and
analyzed by a pathologist (TC) blinded to the experimental
groups. The slides were scanned and images were acquired by a
Hamamatsu NanoZoomerSQ slide scanner. The classification of
lesions followed previously published criteria (36–42).
Measurement of Serum Bone Turnover and
Resorption Markers
Bone turnover was analyzed by quantifying the levels of
tartrate-resistant acid phosphatase 5b (TRACP-5b), procollagen
type 1 amino-terminal propeptide (P1NP), and C-terminal
cross-linked telopeptide of type I collagen (CTX-I) in serum
using ELISA (Immunodiagnostic System, Boldon, UK).
All commercial assays were performed according to the
manufacturers’ instructions, and standard curves were generated
using the supplied reference concentrations. Measurement
was performed using a plate reader Infinite M200 (Tecan,
Mannedorf, Switzerland).
Statistical Analysis
Normality distribution was assessed by D’Agostino and Pearson
test. The treated groups (celastrol 1, 2.5, 5, and 7.5 ug/g)
were compared against the untreated arthritic group with the
Mann–Whitney test with Bonferroni correction to account
for multiple comparisons, as previously reported (17). Thus,
applying the Bonferroni correction, we divided the global
significance level at 0.05 by the number of independent tests
(n = 4) to get the Bonferroni critical value of p < 0.0125,
below which a test would be significant. In addition, the
Mann–Whitney test was also used to compare differences
between the other two independent groups: healthy non-
arthritic and untreated arthritic rats. For paired samples
(e.g., different time points), we have used the Wilcoxon
matched-pairs signed-rank test. In these cases, p < 0.05
were considered to be significant. All statistical analyses were
performed using the GraphPad Prism V.5.01 (GraphPad,
California, USA). Data were presented as median with
interquartile range.
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RESULTS
Oral Celastrol Improved the Clinical
Outcome and Ameliorated the
Histopathological Aspects of AIA Rats
The onset of arthritis in the contralateral ankle joint to the
injection site occurred approximately at day 8 post-disease
induction. As demonstrated in Figure 1A, all animals showed
clinical signs of arthritis by the 4th day of disease induction, and
after 10 days, the untreated arthritic group showed accelerated
disease progression. In contrast, after 6 and 7 days of treatment,
the rats treated with 2.5 and 5 µg/g/day (p = 0.0111 and
p = 0.006) and 7.5 µg/g/day(p = 0.010) of celastrol showed
a significant lower inflammatory score compared to untreated
arthritic rats. Of note, oral celastrol at 1 µg/g/day had no effect
in arthritis progression. After 3 days of treatment, all animals
(5 out of 5) treated with a dose of 25 µg/g/day and 3 animals
(3 out of 5) treated with 12.5 µg/g/day were euthanized due
to progressive weight loss (over 15% of body weight), onset of
diarrhea and respiratory distress. In the group of animals treated
with 7.5 µg/g/day of celastrol, only one animal (1 out of 5) was
euthanized after 10 days of treatment with the same clinical signs.
After 14 days of treatment, the dosage ranging from 2.5 to
7.5 µg/g/day showed a significant anti-inflammatory effect, as
assessed by the evaluation of the clinical inflammatory score
(p = 0.0023 with 2.5 µg/g/day, p = 0.0016 with 5 µg/g/day, and
p = 0.0028 with 7.5 µg/g/day vs. arthritic animals, as shown
in Figure 1B) and also by the measurement of ankle perimeter
(p = 0.0053 with 2.5 µg/g/day, p = 0.0053 with 5 µg/g/day and
p = 0.0118 with 7.5 µg/g/day vs. untreated arthritic animals, as
shown in Figure 1C).
Of note, no differences were observed in body weight after
14 days of treatment, comparing each dose of celastrol (up to
7.5 µg/g/day) with the vehicle control animals (Figure S1A).
Additionally, when comparing, within the same group, the first
and last day of treatment, we were able to observe an increase
in body weight in healthy rats (p = 0.0078, Figure S1B) and
a significant weight loss in the untreated arthritic group, as
expected (p = 0.0074, Figure S1C). However, no weight loss was
observed in AIA animals treated with celastrol using doses up to
7.5 µg/g/day (Figures S1D–G).
As shown in Figure 2, synovial hyperplasia and marked
inflammatory cell infiltration were seen in tibiotarsal joints of
untreated arthritic rats (p = 0.0019 and p = 0.0001 vs. healthy
controls, respectively), also associated with significant bone
erosion (p= 0.0008 vs. healthy controls). In contrast, in celastrol-
treated rats, inflammatory infiltrates were reduced in all dose
regimens, except for the 1µg/g/day group (Figure 2A, p= 0.0010
in 2.5 µg/g/day, p = 0.0006 in 5 µg/g/day and p = 0.0016 in 7.5
µg/g/day vs. arthritic rats). We also observed a reduction in the
number of cells present in the synovial lining layer with the dose
of 2.5 µg/g/day (Figure 2B, p = 0.0110 vs. arthritic rats), and a
marked tendency to decrease in the 5 and 7.5 µg/g/day doses
(p = 0.0220; p = 0.0225, respectively, vs. arthritic rats). These
concentrations of celastrol were also effective in preventing bone
articular destruction (Figure 2C, p = 0.0053 in 2.5 µg/g/day,
p = 0.0069 in 5 µg/g/day, and p = 0.0118 in 7.5 µg/g/day vs.
arthritic rats), with animals presenting a normal joint structure
at the end of the study period (Figure 2D, p = 0.0028 in 2.5
µg/g/day, p = 0.0048 in 5 µg/g/day, and p = 0.0041 in 7.5
µg/g/day vs. arthritic rats).
In addition, we observed that animals treated with celastrol
in the dose range between 2.5 and 7.5 µg/g/day have reduced
synovial cell proliferation, as assessed in the tibiotarsal joints by
Ki67 immunostaining (p = 0.0020, p = 0.0055, and p = 0.0026
vs. arthritic animals, respectively) (Figure 2E).
Finally, we observed that untreated arthritic rats had a
higher number of infiltrating CD68+ synovial macrophages as
compared to healthy controls (p= 0.0001) (Figure 2F). Celastrol
administration was associated with a significant decrease in the
number of CD68+ macrophages infiltrating the arthritic joint
(p= 0.0014 in 2.5µg/g/day, p= 0.0095 in 5µg/g/day vs. arthritic
rats; for the 7.5 µg/g/day there is a strong tendency although not
reaching significance, p= 0.0213).
Oral Celastrol Reduced the Number of
Joint Osteoclasts and Osteoblasts
The immunolocalization of osteoclasts and osteoblasts in
subchondral bone tissue at the tibia/talus region was performed
to evaluate a possible celastrol dose-dependent effect on
bone remodeling. Untreated arthritic rats showed increased
osteoclast numbers (cathepsin k+ cells) in the tibiotarsal bones
(p= 0.004 vs. healthy controls, Figure 3A). Importantly, celastrol
administration was associated with a significant decrease in
the number of osteoclasts, to levels similar to healthy controls
(p = 0.004 in 5 µg/g/day and p = 0.004 in 7.5 µg/g/day vs.
arthritic rats). Untreated arthritic rats also showed increased
numbers of osteoblasts (osteocalcin-positive cells) (p = 0.0005
vs. healthy controls, Figure 3B), a phenotype also reversed by
celastrol administration, with a significant reduction in the
number of osteoblasts as compared to AIA rats (p = 0.0005 in 5
µg/g/day and p= 0.0005 in 7.5 µg/g/day) reaching levels similar
to healthy controls. In the case of rats treated with celastrol at the
dose of 2.5 µg/g/day there is a tendency toward a decrease in the
number of osteoblasts that did not reach statistical significance
(p= 0.02 vs. untreated AIA rats).
Oral Celastrol Reduced Bone Turnover and
Resorption Markers in AIA Rats
In untreated arthritic rats, there was no significant increase in
TRACP-5b levels at the end of the study period (Figure 4A).
Importantly, both 5 and 7.5 µg/g/day doses of celastrol reduced
TRACP-5b levels, when compared with untreated arthritic
rats (p = 0.0031 and p = 0.0065, respectively), suggesting a
decrease in bone resorption. In addition, the elevated levels of
P1NP observed in untreated arthritic rats in comparison with
healthy controls (p = 0.0074, Figure 4B) presented a marked
tendency to decrease with the celastrol dose of 5 µg/g/day
(p = 0.0145 vs. untreated arthritic animals). In accordance,
celastrol administration was able to significantly reduce the
CTX-I levels (p = 0.0079 for 5 µg/g/day, Figure 4C) and also
induced a strong tendency to decrease with the 7.5µg/g/day dose,
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FIGURE 1 | Oral celastrol significantly improved the clinical outcome in adjuvant-induced arthritis rats. The inflammatory score measured throughout the treatment
period (A), the inflammatory score (B), and the ankle perimeter (C) evaluated by day 22 after disease induction showed that the range of dosage between 2.5 and 7.5
µg/g/day was effective in preventing arthritis progression. Healthy N = 8, arthritic N = 17, celastrol 1 µg/g/day N = 5, celastrol 2.5 µg/g/day N = 5, celastrol 5
µg/g/day N = 5, celastrol 7.5 µg/g/day N = 5, celastrol 12.5 µg/g/day N = 5, and celastrol 25 µg/g/day N = 5. The data are shown as median with interquartile
range. The differences were considered as statistically significant for p < 0.05, according to Mann–Whitney tests for comparisons between healthy and arthritic
groups and p < 0.0125 according to Mann–Whitney tests with Bonferroni correction for comparisons between arthritic and celastrol-treated groups. *p < 0.05 and
p < 0.0125.
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FIGURE 2 | Oral celastrol treatment ameliorated the histopathological aspects of adjuvant-induced arthritis (AIA) rats and reduced synovial CD68+ macrophages.
Celastrol significantly impaired inflammatory cell infiltration (A), was associated with a number of synovial lining layers similar to normal values (B), and reduced bone
erosions (C), thus preserving the normal joint structure (D). The celastrol-treated AIA rats showed a significant reduction in synovial cell proliferation as assessed by
the Ki67 marker (E) and in the number of synovial CD68-positive cells (F). Healthy N = 8, arthritic N = 17, celastrol 1 µg/g/day N = 5, celastrol 2.5 µg/g/day N = 5,
celastrol 5 µg/g/day N = 5, and celastrol 7.5 µg/g/day N = 4. The data are expressed as median with interquartile range. The differences were considered as
statistically significant for p < 0.05, according to Mann–Whitney tests for comparisons between healthy and arthritic groups and p < 0.0125 according to
Mann–Whitney tests with Bonferroni correction for comparisons between arthritic and celastrol-treated groups. *p < 0.05 and p < 0.0125.
Frontiers in Medicine | www.frontiersin.org 6 September 2020 | Volume 7 | Article 455
Cascão et al. Efficacy and Toxicity of Celastrol
FIGURE 3 | Oral celastrol reduced the number of osteoclasts and osteoblasts in arthritic joints. Cathepsin k-positive cells (A) and osteocalcin-positive cells (B) were
identified in arthritic joints by immunohistochemistry. Celastrol treatment significantly reduces both types of cells in the doses of 5 and 7.5 µg/g/day. The paw samples
were collected at the time of sacrifice. Healthy N = 8, arthritic N = 17, celastrol 1 µg/g/day N = 5, celastrol 2.5 µg/g/day N = 5, celastrol 5 µg/g/day N = 5, and
celastrol 7.5 µg/g/day N = 4. The data are expressed as median score with interquartile range. The differences were considered as statistically significant for
p < 0.05, according to the Wilcoxon signed-rank tests for comparisons between healthy and arthritic groups and p < 0.0125 according to Mann–Whitney and
Wilcoxon signed-rank tests with Bonferroni correction for comparisons between arthritic and celastrol-treated groups. *p < 0.05 and p < 0.0125.
FIGURE 4 | Oral celastrol was associated with the reduction of bone turnover and resorption markers. TRACP-5b (A), P1NP (B), and CTX-I (C) levels were quantified
in rat serum samples collected at the time of sacrifice. Celastrol seems to reduce the levels of TRACP-5b, P1NP, and CTX-I in the treated animals in comparison with
the arthritic rats. Healthy N = 8, arthritic N = 17, celastrol 1 µg/g/day N = 5, celastrol 2.5 µg/g/day N = 5, celastrol 5 µg/g/day N = 5, and celastrol 7.5 µg/g/day
N = 4. The data are expressed as median with interquartile range. The differences were considered as statistically significant for p < 0.05, according to
Mann–Whitney tests for comparisons between healthy and arthritic groups and p < 0.0125 according to Mann–Whitney tests with Bonferroni correction for
comparisons between arthritic and celastrol-treated groups. *p < 0.05 and p < 0.0125.
(p= 0.0159) when compared with untreated arthritic rats, which
showed an accelerated bone turnover with high levels of CTX-I
(p = 0.0016 vs. healthy controls). Also, the CTX-I serum levels
had a tendency toward a decrease at 2.5 µg/g/day, but it did not
reach statistical significance.
Higher Dose of Celastrol Was Associated
With Signs of Toxicity
A histopathological analysis of selected organs showed
histological changes associated with the disease model and
histological changes associated with the test compound.
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Concerning the disease-related histopathological aspects,
giant-cell granulomas were seen in liver, lung, and spleen
in all groups, with varied severity unrelated with treatment
or dose levels (Figure S2). Grossly, multiple gray to gray-
brown foci were observed over the pleural surface of the
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lung and the surface of the liver and spleen. Microscopically,
these changes corresponded to the variably sized multifocal
to coalescing granulomas, characterized by dense aggregates of
mostly macrophages admixed with frequent multinucleated giant
cells and fewer lymphoid cells (Figure S3). In the liver, these
granulomas were present in the parenchyma; in the lung, they
were mostly arranged around bronchioles, around or adjacent to
large vessels; and in the lung interstitium and in the spleen they
were mostly seen in the red pulp.
Regarding possible celastrol-induced histopathological
aspects, lesions were seen exclusively in the thymus and the liver
of medium- to high-dose groups, and the severity grade was
related with dose (Figure S4). The thymus showed lymphocyte
necrosis, multifocal, and mild to moderate depletion of
lymphocytes in the cortical zone. Severity ranged from moderate
to marked and was seen exclusively in two of six animals of
the high-dose group (7.5 µg/g/day) (Table 1). In the liver, mild
lymphocyte-rich peribiliary inflammatory cell infiltration, and
bile duct hyperplasia were only seen in two and three out of
five animals, respectively, in the 2.5 µg/g/day dose-level group
(Table 1). Higher toxicity incidence was observed in the 5 and
7.5 µg/g/day dose groups, with a toxicity severity grade ranging
from mild to moderate in the medium dose and from mild to
marked in the high dose. Due to the design of the experiment
and to the use of an acute rat model of arthritis, which rapidly
progresses and resolves, it was not possible to assess if changes
associated with celastrol treatment were reversible as no analysis
FIGURE 5 | Serum biochemistry for liver, renal, and cardiac markers upon oral administration of celastrol. The serum levels of ALT (A), CK (B), LDH (C), urea (D), and
pro-ANP (E) were measured by ELISA to evaluate liver, kidney, and cardiac toxicity. Only the levels of LDH were increased in animals treated with 7.5 µg/g/day of
celastrol. Healthy N = 8, arthritic N = 10, celastrol 1 µg/g/day N = 5, celastrol 2.5 µg/g/day N = 5, celastrol 5 µg/g/day N = 5, and celastrol 7.5 µg/g/day N = 4.
The data are expressed as median with interquartile range. The differences were considered as statistically significant for p < 0.05, according to Mann–Whitney tests
for comparisons between healthy and arthritic groups and p < 0.0125 according to Mann–Whitney tests with Bonferroni correction for comparisons between arthritic
and celastrol-treated groups. *p < 0.05 and p < 0.0125.
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was done after suspension of the compound. No significant
histological changes were seen in any other organs.
Moreover, the serum biochemistry for ALT, urea, pro-ANP,
and CK showed levels within the reference range of the
laboratory for this strain/species (Figures 5A,B,D,E). LDH was
increased at the dosage level of 7.5 µg/g/day (as shown in
Figure 5C, p = 0.0062 vs. untreated arthritic rats, respectively).
The electrocardiogram remained unaltered in celastrol-treated
animals (data not shown).
DISCUSSION
In this study, we aimed to determine the therapeutic oral dose
of pure celastrol and the associated toxicity signs in the AIA
rat model.
The doses of celastrol were extrapolated from the
intraperitoneal dose used in our previous studies (7, 8, 17),
also taking into consideration the bioavailability and the
pharmacokinetics of pure celastrol upon oral administration in
rats (22).
We observed that, after 3 days of treatment, all animals
treated with 25 µg/g/day of celastrol and more than 50% of those
treated with 12.5 µg/g/day showed a significant decline in health
status, with progressive weight loss, diarrhea, and respiratory
distress, all of these unrelated with the disease model, and were
euthanized. These data suggest that the dose of 25 µg/g/day is
the lethal dose (LD) and the dose of 12.5 µg/g/day is the LD50 for
the oral administration of pure celastrol, and these dose groups
were therefore excluded from this study. After 10 days under
celastrol treatment, one out of five rats treated with 7.5 µg/g/day
also presented similar clinical signs and was euthanized.
We have observed that the oral dose of 1 µg/g/day of celastrol
was not effective in the treatment of arthritis. In contrast, the
oral doses of 2.5, 5, and 7.5 µg/g/day showed significant anti-
inflammatory properties as assessed by the evaluation of the
inflammatory score and ankle swelling. Most of the inflammatory
and bone-related parameters showed a dose-dependent effect.
However, in some of the analyses, this effect did not reach
statistical significance, which might be due to the smaller sample
size in these groups. The celastrol doses of 2.5, 5, and 7.5µg/g/day
were able to reduce synovial cell infiltration and proliferation and
also decreased bone erosions in joints. Importantly, at the doses
of 2.5 and 5 µg/g/day and with a strong tendency at the dose of
7.5 µg/g/day, celastrol reduced the number of sublining CD68+
synovial macrophages, a biomarker of clinical response (18–20).
These data suggest that, at these oral dosages, celastrol is effective
for the treatment of arthritis. Additionally, the doses of 5 and
7.5 µg/g/day reduced the number of osteoclasts and osteoblasts
present in joint tissues. This observation is in agreement with
the reduction of the bone resorption marker TRACP-5b and also
with the decrease of the bone resorption marker CTX-I in the 5
µg/g/day treated group and a tendency to diminish also at the
7.5 µg/g/day dose, suggesting the control of the accelerated bone
turnover characteristic of arthritis. Our results are in line with
others, where circulating levels of TRACP-5b are not affected
by arthritis induction, contrarily to the marked osteoclastic
activity occurring in this arthritic model. However, there are
increased levels of TRACP-5b in the protein extracts obtained
from inflamed joints (43). These findings suggest that TRACP-5b
reflects bone resorption more accurately when measured locally
rather than systemically (43, 44). Regarding TRACP-5b, CTX-I,
and P1NP results, celastrol might have a direct effect on bone
metabolism in the setting of inflammation. Importantly, these
results suggest that the oral administration of celastrol is also
able to contribute to the prevention of bone damage, as we have
previously demonstrated using AIA rats under treatment with 1
µg/g/day of celastrol via intraperitoneal route (17).
Some inflammatory disturbances were still noted in the
treated animals. This is a consequence of the inflammatory
process that occurred during the first days after disease induction
(from day 0 up to day 8) but before celastrol treatment. This
is in accordance with our previous observations showing that
inflammation induces changes since the first days of arthritis
development (45, 46).
Several studies have demonstrated that celastrol has cellular
targets in the context of RA, such as TAK1/IKK andMAPK/MEK
pathways as well as MMP-9, STAT3, RANKL, and MD2/TLR4,
interfering with the production of cytokines, chemokines,
and inflammatory mediators; inhibiting cell invasion and
proliferation; and suppressing bone resorption (5, 9, 14, 47).
In accordance, Liu et al. have observed in a mouse model of
dexamethasone-induced secondary osteoporosis that celastrol
not only improves lipid metabolism and reduces hypercalciuria
but also mitigates articular cartilage lesions, decreases NF-kB,
MMP-1, and MMP-9 expression, and reduces serum PTH,
TRACP-5b, CTX-I, as well as deoxypyridinoline (48). In 2012,
our group showed that celastrol decreases the secretion of
both IL-1β and TNF in the THP-1 macrophage-like cell line
associated not only with NF-kB inhibition but also with caspase-1
inactivation (7).
Despite its promising anti-arthritic effects, celastrol has been
reported to induce weight loss in mice models of cancer (28, 49–
51). At these dosages of celastrol, no body weight variations
were observed, suggesting no major toxicological effects induced
by celastrol or by the solvents (ethanol and PEG400) used.
These two agents are the most commonly employed (52) and
were identified as the adequate ones for dissolving celastrol
(22). However, some studies have suggested that ethanol and
PEG400 may be deleterious for the gastrointestinal tract (53,
54), constituting a risk factor for toxicological side effects such
as body weight loss. Since no variations in body weight were
observed in celastrol-treated rats and due to the short-term
treatment duration of this study, together with the fact that
we have used the minimum PEG and ethanol concentrations
required in order to get celastrol solubility, we can exclude
this deleterious side effect in the gastrointestinal tract. No
clinical chemistry or histopathological toxicity of this compound
has been previously shown. In parallel with the assessment
of the therapeutic effect of celastrol at different dose levels,
we also assessed its possible toxic effects at the same doses
(1–7.5 µg/g/day). No changes in ALT and blood urea were
detected, suggesting that it did not induce major liver or
renal damage. Celastrol blocks the ion conduction of cardiac
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Kir2.1 and hERG potassium channels and reduces channel
density on the cell surface upon chronic treatment (26),
which may predict cardiotoxicity. However, the CK and the
pro-ANP levels were normal and the electrocardiogram was
unremarkable. LDH was increased in the lower and higher
doses of celastrol. LDH is a very unspecific blood marker,
and the interpretation of this result as a sign of toxicity is
dubious (55).
However, the dose of 7.5µg/g/day was associated withmarked
histopathologic lesions in the thymus and liver of some animals.
The significance of these observations is still unclear and they
have not been reported before. Model-dependent aspects cannot
be excluded, and their physiologic impact on the immune system
and liver is still uncertain.
In accordance with our data, similar evidences were obtained
in a study that tested the efficacy and the safety of four TW
preparations in collagen-induced arthritis rats (56). The authors
have concluded that all plant preparations were effective in
the treatment of inflammation, with no obvious hepatotoxicity
or nephrotoxicity. The clinical experience with the use of TW
extracts in RA patients has shown that there are improvements
in symptoms and physical function. In general, the most frequent
side effects reported in these clinical trials were gastrointestinal
disturbances. (2, 3, 57–60) More recently, a study has shown that
a combination therapy of TW extracts and methotrexate (MTX)
is more effective than MTX alone (4, 61). This can be a strategy
to lower the dose of TW extracts or of celastrol, thus limiting the
side effects.
To more extensively evaluate the safety of orally administered
celastrol, male rats could be included to provide information
on gender-specific toxic effects and other animal models could
explore different toxicity profiles. The acute AIA rat model
of arthritis is not an adequate model to study the long-term
safety and toxicity profile. Thus, the evaluation of a chronic
arthritic model would be also useful to assess the effect of
longer exposure and the existence of reversible side effects.
Moreover, the administration of celastrol in healthy non-arthritic
rats might further determine the adverse/side effects only related
to the compound.
In conclusion, the results showed that 2.5 µg/g/day is the
lowest effective oral dose of pure celastrol, with severe toxicity
signs arising at 7.5 µg/g/day, suggesting a narrow therapeutic
window. It would be now relevant to test this compound in
the setting of a chronic model of arthritis using low doses in
association with MTX.
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